J&J and Pfizer Navigate Growth and Patent Challenges in Healthcare Sector

Johnson & Johnson (JNJ) and Pfizer (PFE) are two healthcare giants with significant exposure to oncology and other therapeutic areas. J&J benefits from a diversified portfolio, including pharmaceuticals and medical devices, which helps it weather economic challenges. Its Innovative Medicine segment is a key growth driver, with sales up 6.2% organically in the first half of 2026, fueled by drugs like Darzalex, Erleada, and Tremfya. New cancer drugs such as Carvykti and Tecvayli are also contributing to top-line growth. Despite headwinds like the Stelara patent cliff and MedTech softness, J&J aims to generate over $100 billion in revenues in 2026 and targets double-digit growth by the end of the decade.

Pfizer, on the other hand, has shifted its business mix post-pandemic, diversifying through internal product launches and strategic acquisitions. The company expects double-digit growth from recently launched and acquired products, with sales up 22% operationally in the first quarter of 2026. Pfizer's oncology pipeline is a significant focus, with plans to establish PF-08634404 as a potential backbone therapy across multiple tumor types. However, Pfizer faces a substantial patent cliff later this decade, with key products like Eliquis, Ibrance, Xeljanz, and Xtandi facing patent expirations, expected to hurt sales by approximately $1.1 billion in 2026.

The Zacks Consensus Estimate for J&J’s 2026 sales implies a 7.4% year-over-year increase, while Pfizer’s estimates suggest a slight decline in sales and earnings. Year-to-date, J&J stock has risen 23.7%, outperforming Pfizer’s 11.7% gain. From a valuation standpoint, Pfizer appears more attractive, but both companies are navigating significant challenges and opportunities in the healthcare sector.